AbbVie stock at EUR 247.50, up 19.1 percent year to date

Published on 10/09/2026 at 19:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock gained 1.91 percent versus EUR 242.85 on October 9, 2026. EUR 247.50 stood before results due October 30, 2026, before the NYSE opens.

Key points in brief

AbbVie stock was at EUR 247.50 at Lang & Schwarz on October 9, 2026, plus 1.91 percent versus EUR 242.85.
The euro price is up 19.1 percent year to date as of October 9, 2026.
AbbVie had a USD 489.5 billion market capitalization and a P/E ratio of 78.1.
JPMorgan raised its target from USD 285 to USD 300 on October 8, 2026.
AbbVie is scheduled to report third-quarter 2026 results on October 30, 2026.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung — AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) was trading at EUR 247.50 at Lang & Schwarz on October 9, 2026 at 7:52 p.m. CEST, plus 1.91 percent versus EUR 242.85. AbbVie stock is up 19.1 percent year to date as of October 9, 2026, giving the latest move a strong position within its annual performance.

Price rises with the market open

The US listing provides a separate currency view. AbbVie was last at USD 277.07 on the NYSE on October 9, 2026 at 1:57 p.m. ET, plus 1.71 percent against its USD 272.42 prior close.

Trading volume was 1,456,410 shares against an average of 4,838,500 shares at the same timestamp. The USD 190.75 to USD 277.60 52-week range puts the latest US price USD 0.53 below the high, a distance of 0.2 percent.

Valuation remains a key divider

AbbVie carried a market capitalization of USD 489.5 billion and a P/E ratio of 78.1 on October 9, 2026. The valuation is materially higher than the comparable figures for Johnson & Johnson and Bristol-Myers Squibb in the same market snapshot.

According to Markets Insider on October 8, 2026, JPMorgan raised its AbbVie target from USD 285 to USD 300 and kept an Overweight rating. The new target lies 8.3 percent above the NYSE price of USD 277.07.

Comparison with peers

AbbVie Inc.: plus 1.91 percent, P/E 78.1, market capitalization USD 489.5 billion

Johnson & Johnson (NYSE, USD): plus 1.78 percent, P/E 30.2, market capitalization USD 629.1 billion

Bristol-Myers Squibb Company (NYSE, USD): plus 0.05 percent, P/E 13.1, market capitalization USD 121.8 billion

Results date sets the next marker

Yahoo Finance reported on October 1, 2026 that AbbVie will publish third-quarter 2026 results on October 30, 2026, before the NYSE opens. The scheduled date gives the market a defined checkpoint after the 19.1 percent year-to-date advance.

AbbVie stock stays near its yearly high

For German-market investors, the euro quote combines a positive daily move with a price still below the US listing's 52-week high. The comparison with Johnson & Johnson and Bristol-Myers Squibb also shows that AbbVie's higher P/E is the clearest valuation difference in this snapshot.

The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.